Workflow
圣诺生物(688117) - 2023 Q1 - 季度财报
SNSWSNSW(SH:688117)2023-04-25 16:00

Financial Performance - The company's operating revenue for Q1 2023 was ¥81,516,580.85, representing a year-on-year increase of 0.96%[5]. - The net profit attributable to shareholders decreased by 1.82% to ¥14,032,925.44, while the net profit after deducting non-recurring gains and losses dropped significantly by 48.25% to ¥6,278,006.01[5][8]. - Total revenue for Q1 2023 was CNY 81,516,580.85, a slight increase of 1.0% compared to CNY 80,744,800.39 in Q4 2022[19]. - Net profit for Q1 2023 was CNY 14,032,925.44, a decrease of 1.8% from CNY 14,292,867.60 in Q4 2022[19]. - The net profit attributable to the parent company for Q1 2023 is CNY 14,032,925.44, compared to CNY 14,292,867.60 in Q1 2022, indicating a slight decrease[20]. - The total comprehensive income attributable to the parent company for Q1 2023 is CNY 14,032,925.44, down from CNY 14,292,867.60 in the same period last year[20]. - The basic and diluted earnings per share for Q1 2023 remain at CNY 0.18, unchanged from Q1 2022[20]. Cash Flow - The net cash flow from operating activities fell by 41.72% to ¥17,230,314.83, attributed to reduced sales collections and increased employee compensation payments[5][8]. - Cash inflows from operating activities for Q1 2023 amount to CNY 229,885,043.78, an increase from CNY 156,155,336.62 in Q1 2022[22]. - The net cash flow from operating activities for Q1 2023 is CNY 17,230,314.83, down from CNY 29,565,224.06 in Q1 2022[22]. - The net cash flow from investing activities for Q1 2023 is -CNY 175,165,401.28, compared to a positive CNY 19,110,356.37 in Q1 2022[23]. - Cash inflows from financing activities for Q1 2023 total CNY 140,000,000.00, significantly higher than CNY 10,000,000.00 in Q1 2022[23]. - The net cash flow from financing activities for Q1 2023 is CNY 127,206,627.92, compared to CNY 9,391,908.39 in Q1 2022[23]. - The ending cash and cash equivalents balance for Q1 2023 is CNY 340,592,596.07, up from CNY 268,158,720.07 at the end of Q1 2022[23]. - The company received CNY 1,439,471.11 in tax refunds during Q1 2023, compared to CNY 77,628.60 in Q1 2022[22]. Assets and Liabilities - The total assets at the end of the reporting period increased by 13.38% to ¥1,256,249,613.62 compared to the end of the previous year[6]. - Total assets increased to CNY 1,256,249,613.62, up from CNY 1,108,008,638.28, reflecting a growth of 13.4%[16]. - Total liabilities rose to CNY 415,445,853.87, an increase of 47.7% compared to CNY 281,271,366.55 in Q4 2022[16]. - The company’s total equity increased to CNY 840,803,759.75 from CNY 826,737,271.73, reflecting a growth of 1.7%[16]. - Long-term borrowings increased significantly to CNY 179,186,416.42 from CNY 48,052,800.00, indicating a strategic shift in financing[16]. Research and Development - The company's R&D investment totaled ¥6,158,199.18, accounting for 7.55% of operating revenue, a slight decrease of 0.01 percentage points[6]. - Research and development expenses for Q1 2023 were CNY 4,862,883.56, slightly down from CNY 5,112,082.43 in Q4 2022[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,815[10]. - Chengdu Sainuo Investment Co., Ltd. held 37.50% of the shares, making it the largest shareholder[10]. Other Information - The company did not disclose any new product developments or market expansion strategies during the reporting period[12]. - The company reported non-recurring gains of ¥7,754,919.43, primarily from government subsidies and other income[7]. - Cash and cash equivalents decreased to CNY 340,592,596.07 from CNY 372,122,126.73, representing a decline of 8.5%[14]. - The company reported a significant increase in inventory, which rose to CNY 159,832,819.20 from CNY 135,434,477.07, marking an increase of 18.0%[14].